CN
Product Service Diagnosis and Treatment BGI PARP Inhibitor CDx-HRD Test
What is Homologous Recombination Repair (HRR) deficiency?
The pathway of Homologous Recombination Repair (HRR) is one of the important pathways of DNA damage repair in the body that is primarily involved in the repair of DNA double-strand breaks.
The well-known BRCA1/2 genes are key genes in the pathway of Homologous Recombination Repair (HRR), and if a deleterious mutation occurs in them, their function in repairing DNA double-strand breaks will be substantially compromised, resulting in Homologous Recombination Repair Deficiency (HRD).
In addition to the BRCA1/2 genes, other gene mutations such as PALB2, RAD51C, RAD51D as well as BRCA1 promoter methylation can also cause HRD, resulting in genomic instability and the generation of genomic scars.
Compared with BRCA1/2 gene testing, HRD testing can screen for and identify





HRD has been included in the NCCN Guidelines
The NCCN Guidelines for Ovarian Cancer V1 2020 state that HRD status can be used to assess whether patients can benefit from PARP inhibitors if the BRCA1/2 test result is negative (Category 2B recommendation).
BGI PARP Inhibitor CDx-HRD Test
Just as an injury would leave a scar on the body, DNA damage that can't be repaired properly also leaves "scarring" at the level of the entire genome. The extent of repair deficiency is assessed by detecting the traces left at the genomic level.
The HRD score test is a recognized method to assess the status of HRD. It combines three indicators: loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST), and fully assesses the status of homologous recombination repair deficiency by detecting mutations in hundreds of thousands of genomic SNP loci.


One-stop solution for Homologous Recombination repair Deficiency status
The HRD score uses information about HRR gene variants to assess the presence of homologous recombination repair deficiency fully and accurately.


Suitable for

    Patients with high-grade serous ovarian cancer
    Patients with triple negative breast cancer
    Patients with solid cancers, such as pancreatic and prostate cancers (RUO)

Sample requirements

    Tumor samples (such as fresh tissue or FFPE), peripheral blood (optional)

Customer Service:

+1 866 301 0097

Service Time:7*24

Language:English

E-mail: info@bgi.com

Copyright © BGI 2022. All Rights Reserved. Guangdong ICP Registration No. 16021117